Cytosorbents (CTSO) Free Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
Cytosorbents (CTSO) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 28.87% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 69.33% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 120.89% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 14.12% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 13.29% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 142.84% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -0.16% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | -11.68% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | -14.34% |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | 53.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 53.90% |
| Mar 31, 2026 | 68.46% |
| Dec 31, 2025 | -104.69% |
| Sep 30, 2025 | 0.80% |
| Jun 30, 2025 | 73.09% |
| Mar 31, 2025 | 23.71% |
| Dec 31, 2024 | 62.94% |
| Sep 30, 2024 | 51.11% |
| Jun 30, 2024 | 28.43% |
| Mar 31, 2024 | -34.75% |
| Dec 31, 2023 | -17.09% |
| Sep 30, 2023 | 27.47% |
| Jun 30, 2023 | 39.63% |
| Mar 31, 2023 | 64.72% |
| Dec 31, 2022 | 20.93% |
| Sep 30, 2022 | -46.75% |
| Jun 30, 2022 | -294.31% |
| Mar 31, 2022 | -269.82% |
| Dec 31, 2021 | -475.83% |
| Sep 30, 2021 | -42.99% |